Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

INTRODUCTION: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-label, multicenter studies in patients with stage 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawitz, Eric, Gane, Edward, Cohen, Eric, Vierling, John, Agarwal, Kosh, Hassanein, Tarek, Mantry, Parvez S., Pockros, Paul J., Bennett, Michael, Kemmer, Nyingi, Morelli, Giuseppe, Zha, Jiuhong, Wang, Deli, Shulman, Nancy S., Cohen, Daniel E., Reddy, K. Rajender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365406/
https://www.ncbi.nlm.nih.gov/pubmed/30775622
http://dx.doi.org/10.1016/j.ekir.2018.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365406/
https://www.ncbi.nlm.nih.gov/pubmed/30775622
http://dx.doi.org/10.1016/j.ekir.2018.10.003

Ejemplares similares